Recent successes in CD19 CAR–T-cell trials have demonstrated the remarkable therapeutic potential of CD19 CAR-T cells and fueled intense interest in the development of CAR–T-cell therapies against additional tumor targets. Here, CD19 is linked to neoplasm.